MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Sarepta Therapeutics Inc

Open

BrancheGesundheitswesen

61.21 1.04

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

59.75

Max

61.86

Schlüsselkennzahlen

By Trading Economics

Einkommen

125M

159M

Verkäufe

191M

658M

KGV

Branchendurchschnitt

23.603

57.333

EPS

1.9

Gewinnspanne

24.156

Angestellte

1,372

EBITDA

138M

187M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+140.04% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-5.3B

5.4B

Vorheriger Eröffnungskurs

60.17

Vorheriger Schlusskurs

61.21

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

Sarepta Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. März 2025, 14:19 UTC

Wichtige Markttreiber

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20. Juni 2024, 23:05 UTC

Wichtige Markttreiber

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21. Juni 2024, 08:58 UTC

Top News

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Sarepta Therapeutics Inc Prognose

Kursziel

By TipRanks

140.04% Vorteil

12-Monats-Prognose

Durchschnitt 148.25 USD  140.04%

Hoch 209 USD

Tief 70 USD

Basierend auf 22 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sarepta Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

22 ratings

18

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

59.31 / 62.78Unterstützung & Widerstand

Kurzfristig

Very Strong Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.